Ocugen has dosed the first patient with retinitis pigmentosa (RP) in its phase 3liMeliGhT trial (NCT06388200) of OCU400 gene therapy.1
Subscribe to:
Post Comments (Atom)
Gene vs. genome
Gene vs. genome: What is the difference? Genes are specific segments of DNA that influence certain aspects of growth and health. Collectivel...
-
Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adeni...
-
Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through ...
-
How do asexual ants maintain genetic diversity? It’s commonly accepted wisdom that genetic diversity is vital for the survival of a species...
No comments:
Post a Comment